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graft-versus-host reactions (GVHD) retaining a graft-versus-leu-
kemia effect and the capacity to reconstitute the immune system.
CD6-depleted mbc contain a large proportion of NK and NK-T
cells. 63 patients with advanced disease (AML 32, ALL 15, NHL
11, CLL 2, CML 2, SAA 1) were transplanted with marrow from
family donors sharing one HLA-haplotype and differing in 0–4
HLA-antigens of the second haplotype. Conditioning consisted of
total body irradiation (TBI), antithymocyte globulin (ATG) and
cyclophosphamide (CY), post-grafting immunosuppression of cy-
closporin A (CSA) and a short course of methotrexate (sMTX). A
transfusion of donor leukocytes was given prior to CY. Complete
engraftment was observed in 34 evaluable patients given 12 Gy
TBI. The dose of TBI could be reduced to 4 Gy without rejection
in 25 evaluable patients. GVHD was severe (grade III and IV) in 12
of 48 evaluable patients. An improved method of CD6-depletion
was administered to mbc in 9 patients and severe GVHD did not
develop. GVHD responded to corticosteroids in most patients. 15
patients survive disease free up to 6 years (median 784 days).
Recurrent infections including PTLD were the major cause of
transplant-related mortality. Absolute counts of lymphocytes, CD4
and CD8 subpopulations were not different from those of a con-
temporary group of 46 patients in advanced disease given HLA-
identical sibling transplants. However naı¨ve CD4 cells and TRECs
were low. Rejection, GVHD and GVL have been controlled by
this regimen, but immune reconstitution remains a problem that
may be solved by early discontinuation of immunosuppression in
this regimen.
GVH/GVL
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ACUTE GRAFT VERSUS HOST DISEASE AFTER NON-MYELOABLATIVE
ALLOGENEIC STEM CELL TRANSPLANTATION (NST) WITH LOW-DOSE
TBI, FLUDARABINE AND ANTITHYMOCYTE GLOBULIN (ATG)
Grosskreutz, C.L.; Scigliano, E.; Fruchtman, S.M.; Isola, L.M. Hema-
tology-Oncology Division, Mount Siani Medical Center, New York, NY.
Acute GvHD is a frequent complication of NST although at a
lower rate and severity than after full myeloablation. ATG given
with conditioning produces substantial host immunosuppression
and is thought to produce T-cell depletion of the allograft. We
previously showed that the addition of ATG to TBI 200 cGy and
ﬂudarabine can improve donor engraftment. Whether it impacts
on acute and chronic GvHD and on graft versus tumor effect is less
known. Forty-seven pts, not eligible for conventional allogeneic
SCT, underwent NST using ATG 15 mg/kg/day (equine) or 1.5
mg/kg/day (rabbit) days 4 to 1, single fraction TBI 200 cGy day
5, ﬂudarabine 30 mg/kg/day days4 to2. Oral MMF and CSA
started on day 5. Allografts were G-CSF mobilized PBSC.
Thirty-two pts (68%) had match related donors, 9 (19%) match
unrelated (10/10), 1 (2%) mismatch related (9/10) and 5 (10.6%)
mismatch unrelated donors (9/10). Twenty-ﬁve pts had sex
matched donors (53.2%). Full donor chimerism was documented
in 85% and partial (50%) in 11% of pts. At a median follow up
of 309 days, GvHD grade II-IV developed in 13 pts (27.6%). Fatal
GvHD of liver and/or gut occurred in 8 pts (17%). The mean age
of pts who developed GvHD was 54 years and 57 for those who did
not (p  ns). The corresponding mean ages for their donors were
47 vs. 50 years (p  ns). Seven out of fourteen (50%) unrelated
transplants recipients and 6/33 (18%) with related donors devel-
oped GvHD (p  0.023). Infectious complications were seen in 8
pts (17%) and were the cause of death in 6 (12%). Thirteen of the
47 pts (27.6%) underwent transplant for AML. Six pts had re-
lapsed/refractory disease at the time of transplant. 3 were in CR2
and 4 in CR1. Eleven pts (84.6%) relapsed with AML after trans-
plant. Previously reported data on NST using 200 cGy of TBI and
ﬂudarabine with no ATG showed an incidence of acute GvHD
grade II-IV of 64% and 24% GvHD related mortality. Similar
rates have been reported with ﬂudarabine and melphalan reduced-
intensity conditioning. In our cohort of 47 pts the addition of ATG
resulted in decreased incidence of acute GvHD grade II-IV and
GvHD related morality without a high rate of infectious compli-
cations. A high incidence of disease relapse in pts with AML may
reﬂect the high proportion of pts with advanced leukemia enrolled
in the study. However, it also warrants further investigation to rule
out that ATG may hinder graft versus leukemia effect.
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SENSITIVE AND QUANTITATIVE CHIMERISM ANALYSIS IN ALL PA-
TIENTS WITH REAL-TIME PCR
Uzunel, M.1; Ulf, S.1; Jonas, M.2; Petter, S.2; Marie, S.1; Dan, H.1;
Olle, R.2 1. Clinical Immunology F79, Stockholm, Sweden; 2. Center for
Allogeneic Stem Cell Transplantation, Stockholm, Sweden.
In this study, we wanted to evaluate the predictive value of a
sensitive chimerism method for relapse in 45 patients with acute
lymphoblastic leukemia (ALL) after allogeneic stem cell transplan-
tation (SCT). The method, based on real-time PCR using single
nucleotide polymorphic (SNP) markers, was shown to be more
than one log more sensitive than the most common used methods.
Mixed chimerism (MC) was detected in the peripheral blood (PB)
and bone marrow (BM) samples of all patients that relapsed. How-
ever, a high degree of MC was also found in patients without
relapse (57% MC in PB and 94% MC in BM). In some patients
still in remission, MC was found 4–5 years after SCT. In paired
BM-PB samples, the level of recipient cells were more than one log
higher in BM as compared to PB. Chimerism results after 3
months post-SCT were associated with relapse. In PB samples,
13/15 patients with a MC level of 0.1% relapsed as compared to
3/22 patients below this level (p
0.001). The median time be-
tween ﬁrst detection of this level and relapse was 5.5 (range 0.3–44)
months. In BM samples, 10/15 patients with a MC level 1%
relapsed as compared to 1/11 patients below this level (p
0.01).
The median time between ﬁrst detection of this level and relapse
was 18 (1.8–34) months. In conclusion, using a new sensitive
chimerism method, a high incidence of MC was found after SCT.
Despite this, threshold levels associated with relapse were found
both in PB and BM. The time period between ﬁrst detection of
these levels and relapse may be long enough for immunotherapeu-
tic interventions to have an antileukemic effect.
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CLINICAL RELEVANCE OF RECIPIENT LEUKOCYTE INFUSION (RLI)
THERAPY
Saito, T.I.; Sykes, M. Transplantation Biology Research Center, Mas-
sachusetts General Hospital/Harvard Medical School, Boston, MA.
Background: Surprisingly, anti-tumor responses can occur in
patients who reject donor grafts following nonmyeloablative he-
matopoietic cell transplantation (Dey et al., Biol Blood Marrow
Transplant 7:604). In murine mixed chimeras prepared with non-
myeloablative conditioning, we previously showed that recipient
leukocyte infusions (RLI) induced anti-tumor responses against
host-type tumors (Rubio et al. Blood 102:2300). To further inves-
tigate the clinical relevance of this RLI model, we 1. evaluated the
effect of RLI from tumor-bearing mice and 2. compared RLI with
allogeneic lymphocyte infusion in untreated mice. Methods:
Mixed chimerism was achieved in BALB/c (H-2d) mice condi-
tioned with depleting anti-CD4 and CD8 mAbs on Day 5,
cyclophosphamide 200 mg/kg on Day 1 and 7 Gy thymic irra-
diation on Day 0 prior to transplantation of 25  106 B10.BR
(H-2k) bone marrow cells. Some groups received RLI (3  107
BALB/c spleen cells) seven weeks post-BMT. Some RLI donor
mice received BALB/c A20 B cell lymphoma cells (1  105) two
weeks before RLI. Some groups received RLI depleted of B cells
by MACS column for purging tumor cells. A20 cells (5 105) were
given i.v. one week after RLI in chimeras or after allogeneic
lymphocyte infusion (3  107 B10.BR spleen cells) to untreated
BALB/c mice. Results: In the clinical setting, RLI would be
obtained from tumor-bearing hosts. We therefore examined
whether RLI is still effective when the lymphocytes are obtained
from tumor-bearing mice. Recipients of RLI from tumor-bearing
mice showed similar tumor survival compared to recipients of RLI
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from naive donors. Thus, with a purging procedure, the same
anti-tumor effect was achieved with RLI from tumor-bearing hosts
as from non-tumor-bearing hosts. Allogeneic lymphocyte injection
is a potentially feasible anti-tumor therapy. We therefore com-
pared anti-tumor effects of allogeneic lymphocyte infusion into
naive mice with that of RLI given to mixed chimeras. RLI recip-
ients had longer survival than naive mice receiving allogeneic
lymphocytes. This result suggests not only that the anti-tumor
effect of RLI therapy is stronger than allogeneic lymphocyte infu-
sion therapy but also suggests that rejection of allogeneic cells is
insufﬁcient and mixed chimerism is required prior to the induced
rejection to achieve maximum anti-tumor effects. Conclusion:
Together, these data reinforce the potential of RLI therapy to be
a new HSCT strategy which does not have the risk of graft-versus-
host disease.
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PREVENTION OF GRAFT VERSUS HOST DISEASE BY ANTIBODY MEDI-
ATED DEPLETION OF ACTIVATED DENDRITIC CELLS
Wilson, J.; Rice, A.M.; Hart, D.N.J.; Munster, D.J. Mater Medical
Research Institute, South Brisbane, Queensland, Australia.
The use of haematopoietic stem cell transplantation as a method
of treating leukaemia is signiﬁcantly limited by its major compli-
cation, graft versus host disease (GVHD). Dendritic cells (DCs)
are a haematopoietic population of antigen presenting cells which,
when activated, stimulate donor T lymphocytes. We have pro-
posed, based on preliminary clinical data (Fearnley Blood 1999;93:
728) that DC warrant investigation as an alternative therapeutic
target to prevent GVHD. To investigate the effect of DC deple-
tion in GVHD, we used an established mouse-human chimeric
model of GVHD in which human T lymphocytes are known to be
effector cells. Brieﬂy, conditioned severe combined immunodeﬁ-
cient (SCID) mice were injected with human peripheral blood
mononuclear cells (PBMC), causing a GVHD-like syndrome that
was measured by mouse survival, clinical scoring and human cell
engraftment. Our novel ﬁnding is that human dendritic cells are
required to cause GVHD in this model. Further, by investigating
the role of various human PBMC populations we have shown that
the GVHD process in this model does not involve; a human
anti-mouse antibody component; human CD8 T lymphocytes; or
human CD14 monocytes. Preliminary data have shown that in-
vitro depletion of human DC using the novel antibody, CMRF-44
(Hock Immunology 1994;83:573) increases survival of mice when
compared to mice treated with unmodiﬁed PBMC (p0.064).
Work is underway to assess the effect of in-vivo depletion of human
DC in this model.
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A MURINE TRANSPLANTATION MODEL OF IN VIVO DENDRITIC CELL
DEPLETION TO ATTENUATE GRAFT VERSUS HOST DISEASE
Turner, B.E.; Burns, A.M.; Atkinson, K.; Munster, D.J.; Hart, D.N.J.;
Rice, A.M. Mater Medical Research Institute, South Brisbane, Queens-
land, Australia.
Patient outcome after haemopoietic stem cell transplantation
(HSCT) is governed by time to engraftment, tumour relapse and
development of graft versus host disease (GvHD). Current immu-
nosuppressive strategies for GvHD patients are centred mainly on
manipulation of the effector T-cell; however, new interest in the
possibility of DC depletion is emerging. Our intention is to shift
the focus from elimination of activated T-cells, to controlling the
DCs that activate these T-cells. We have previously shown that
immunoregulatory DC subsets exist in mice and these may be
manipulated in a transplant setting. In addition, we have also
shown one DC subset in particular, the mature plasmacytoid DCs,
to be increased in mouse spleen after conditioning by radiation.
The purpose of this study is to develop novel strategies to deplete
candidate DC subsets in order to control GvHD and improve
outcomes for HSCT recipients. Intra-peritoneal (ip) injection of
N418, a monoclonal antibody against mouse leukocyte integrin
CD11c, or NLDC-145 (DEC-205) is expected to deplete murine
DC in vivo. Dendritic cell depletion by ip injection of N418 cannot
be monitored using a commercial anti-CD11c-APC conjugate due
to epitope blocking. This problem was overcome using a complex
staining matrix of DC markers which include MHCII, 33D1,
DEC205, CD4, CD8a, CD11b, CD45R (B220) and Gr-1 to iden-
tify sub-populations of CD11c. Recent results show up to 50%
depletion of murine DC using these antibodies. The effect of this
on GvHD is being examined.
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USE OF INFLIXIMAB/DACLIZUMAB COMBINATION FOR THE TREAT-
MENT OF ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASE OF THE
LIVER AND GUT
Rodriguez, V.; Trotz, B.; Anderson, P.M.; Arndt, C.A.S.; Allen, J.;
Khan, S.P. Department of Pediatric and Adolescent Medicine, Division
of Pediatric Hematology-Oncology, Pediatric Blood and Bone Marrow
Transplant Program, Rochester, MN.
We report the use of Inﬂiximab/Daclizumab combination for the
treatment of acute and chronic graft versus host disease (GVHD)
of the liver and gut in two children who failed standard GVHD
therapy. Inﬂiximab was given at a dose of 10 mg/kg weekly 4 and
Daclizumab 1 mg/kg days 1, 4, 8, 15, 22. Patient #1 (Pt) developed
grade 2 chronic GVHD of the liver a year after his third allogeneic
HLA-matched sibling bone marrow transplant (BMT) for relapsed
juvenile myelomonocytic leukemia. Despite immunosuppressive
therapy with FK506, mycophenolate mofetil and prednisone 2
mg/kg/dose, liver enzymes failed to normalize. Within 1 week of
initiation of therapy with Inﬂiximab/Daclizumab, liver enzymes
and bilirubin normalized. Pt #2 developed acute GVHD of the
liver and gut grade 3 day 37 after allogeneic-HLA matched
sibling BMT for Philadelphia positive acute lymphoblastic leuke-
mia. Pt did not show clinical response despite the addition of
prednisone 2 mg/kg/dose to his immunosuppressive regimen. Res-
olution of acute GVHD was observed within two weeks of initia-
tion of Inﬂiximab/Daclizumab. Both patients tolerated the regimen
well with no toxicities and were off immunosuppression 8 and 11
months respectively from the initiation of therapy for GVHD. We
conclude that the combination of Inﬂiximab/Daclizumab seems to
be effective in the treatment of acute and chronic GVHD of the
liver and gut. Future prospective studies in a larger cohort of
patients are needed to conﬁrm this observation.
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GRAFT-VERSUS-HOST DISEASE AFTER NONMYELOABLATIVE HEMATO-
POIETIC STEM CELL TRANSPLANTATION
Na, I.I.; Shn, H.; Song, E.K.; Lee, K.W.; Yoon, S.S.; Lee, J.S.; Park, S.;
Kim, B.K. Seoul National University Hospital, Seoul, Republic of Korea.
Purpose: To evaluate the incidence, severity and response to
therapy of GVHD following NST. Methods: We evaluated ﬁfty-
eight patients transplanted using the ﬂudarabine based condition-
ing regimen between Oct 2000 and Feb 2004; GVHD prophylaxis
was done using cyclosporin (5 mg/kg-3 mg/kg iv or po from day
1 to 90). Patients underwent NST because of old age, comor-
bidities or advanced stage of the disease at the time of transplant.
There were 37 males and 21 females with an age range of 17–66
years (median 48). Results: Incidence of grades II-IV acute
GVHD and chronic GVHD was 34% and 70%, respectively.
Grade 1–2 and 3–4 acute GVHD was observed in 4 and 12
patients, respectively. Chronic GVHD was observed in 23 patients.
11 (70%) and 5 (21%) patients of acute and chronic GVHD
showed no response despite treatment. Cumulative incidence rates
of death with manifestations of GVHD under treatment were 50%
at 15 months. With a median follow-up of 195 days, the 3-year
estimates for overall survival were 32%. Conclusion: The inci-
dence of grade II-IV acute GVHD in Korea may be less than in
Western countries. But acute GVHD responded poorly and
GVHD related death rates were fairly high. Further studies are
needed to improve the eventual outcome not only of acute but also
of chronic GVHD following NST.
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